Clinical Trial Update: 18F-DOPA II - PET Imaging Optimization [Phase 3]

View source ↗

Summary

Phase 3 trial of the imaging agent 18F-DOPA II for PET imaging optimization is currently recruiting, sponsored by the University of Alberta, for several conditi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Tumor
• Congenital Hyperinsulinism
• Lewy Body Disease
• Neuroblastoma
• Neuroendocrine Tumors
• Parkinson Disease

Drugs mentioned

• 18F-DOPA II

Snippet

Sponsor: University of Alberta | Conditions: Congenital Hyperinsulinism, Neuroblastoma | Phase 3 | Status: RECRUITING